Peter L. Salgo, MD: Now, something you said rang a bell, because Tom mentioned something, too. You said it’s a chronic disease and you’re never going to get cured, and yet there’s a time limit on ...

Urologist-level variation in androgen deprivation therapy intensification in patients with metastatic hormone-sensitive prostate cancer: A retrospective, population-based cohort study in Ontario, ...

Expert Rev Endocrinol Metab. 2009;4(6):639-650. Osteoporosis results in over nine million fractures per year at a cost of more than US$50 billion. Bone mass and strength are maintained by the bone ...

Traditional therapies for bone metastasis, which include surgery, radiotherapy and bisphosphonate treatment, have been largely palliative rather than curative. Clinical evidence now suggests that ...

The human monoclonal antibody denosumab decreases bone resorption independently of previous treatment with bisphosphonates in patients with bone metastases. Bone metastases increase osteoclast ...

Current treatments for osteoporosis are hampered by low compliance; new therapies that have a higher compliance are, therefore, required. Denosumab targets RANKL (receptor activator of nuclear factor ...

Primary biliary cholangitis (PBC) is a chronic cholestatic disorder in which symptoms exert a direct influence on patients’ quality of life. Beyond pruritus and fatigue, patients with PBC are also ...

Clinical performance, efficacy, and safety of the DigniCap system, a scalp-hypothermia system, in preventing chemotherapy (CTX)-induced alopecia in patients (pts) with early-stage breast cancer (BC).